Is it safe? Parents worry about risks as schools, camps reopen TODAY 5/10/2021 Lisa Tolin
Don’t touch that. Wash your hands for 30 seconds. Where’s your mask? Six feet, please.
Parents who spent the last year carefully protecting their children from the COVID-19 pandemic are now being asked to send them back to daycare, school and camps, all without the benefit of vaccines. It s cause for celebration, but also, for many, worry.
As life resumes some normal rhythms, the world seems split among those who can’t wait to get back to “normal” and those who remain wary, even anxious, about returning to life as we knew it. For parents, there’s the added worry about unvaccinated children.
Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™
- Evrysdi increased survival and reduced need for permanent ventilation -
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 15, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy (SMA) treated with Evrysdi™ (risdiplam) obtained increases in survival and sustained improvements in achieving key motor milestones, including head control, sitting, rolling over, and further developing towards acquiring the ability to stand, and walk. Data were presented at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting.
iii
MISSISSAUGA, ON, April 15, 2021 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has granted EVRYSDI
Ⓡ (risdiplam) market authorization for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.
iii
EVRYSDI works by helping the body make more of a protein called, SMN protein. EVRYSDI increases and sustains the amount of SMN protein in the body, which helps to treat SMA. It is the first medicine for SMA that can be taken at home and is administered once daily by mouth or feeding tube.
iii The Health Canada approval of EVRYSDI is a welcome addition in our ability to treat SMA. It is an efficacious treatment that significantly increases survival motor neuron (SMN) protein in SMA patients, said Dr. Hugh McMillan, Pediatric Neurologist at the Children s Hospital of Eastern Ontario. We now have an additional and convenient treatment option with EVRYSDI, as it s the first at-home and oral option for patients
Share:
More than twice as many babies (61% vs. 29%) were able to sit without support for at least five seconds after 24 months compared to 12 months of treatment
Evrysdi increased survival and reduced need for permanent ventilation
Evrysdi has proven efficacy across adults, children and babies 2 months and older
Basel, 15 April 2021 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi™ (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation . Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalisations compared to the natural course
F. Hoffmann-La Roche Ltd: Roche s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
Evrysdi increased survival and reduced need for permanent ventilation
Evrysdi has proven efficacy across adults, children and babies 2 months and older
Basel, 15 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation . Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalisations compared to the natural course of Type 1 SMA. Safety f